A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis

International Journal of Antimicrobial Agents

Volumn 37, Issue 3, 2011, Pages 266-269

  Bryant, Alexander M ^a,c   Slain, Douglas ^b   Cumpston, Aaron ^a   Craig, Michael ^a  

^a WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c ST JOHN S MERCY MEDICAL CENTER   (United States)

Author keywords

Antifungal prophylaxis; Antifungals; Posaconazole; Therapeutic drug monitoring

Indexed keywords

CASPOFUNGIN; HISTAMINE H2 RECEPTOR ANTAGONIST; POSACONAZOLE; PROTON PUMP INHIBITOR; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANDIDA GLABRATA; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE INCREASE; FEMALE; HUMAN; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PERITONITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE; STRESS ULCER;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIFUNGAL AGENTS; DRUG MONITORING; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 79951949693     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.11.021     Document Type: Article

References (15)

1. O.A. Cornely, J. Maertens, D.J. Winston, J. Perfect, J. Ullmann, and T.J. Walsh Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 2007 348 359 (Pubitemid 46148777)
2. G.R. Thompson, M.G. Rinaldi, T.F. Patterson, and J.S. Lewis Posaconazole therapeutic drug monitoring: a reference laboratory experience Antimicrob Agents Chemother 53 2009 2223 2224
3. R. Courtney, D. Wexler, E. Radwanski, J. Lim, and M. Laughlin Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults Br J Clin Pharmacol 57 2003 218 222
4. G. Krishna, A. Moton, L. Ma, M.M. Medlock, and J. McLeod Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob Agents Chemother 53 2009 958 966
5. M.A. AbuTarif, G. Krishna, and P. Statkevich Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome Curr Med Res Opin 26 2010 397 405
6. G. Krishna, M. Abu Tarif, F. Xuan, M. Martinho, D. Angulo, and O.A. Cornely Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome Pharmacotherapy 28 2008 1223 1232
7. D. Lebeaux, F. Lanternier, C. Elie, F. Suarez, A. Buzyn, and J.P. Viard Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults Antimicrob Agents Chemother 53 2009 5224 5229
8. D. Andes, A. Pascual, and O. Marchetti Antifungal therapeutic drug monitoring Antimicrob Agents Chemother 53 2009 24 34
9. S.H. Jang, P.M. Colangelo, and J.V.S. Gobburu Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma Clin Pharmacol Ther 88 2010 115 119
10. G. Krishna, M. Martinho, P. Chandrasekar, A.J. Ullmann, and H. Patino Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease Pharmacotherapy 27 2007 1627 1636 (Pubitemid 350234311)
11. V. Kohl, C. Muller, O.A. Cornely, K. Abduljalil, U. Fuhr, and J.J. Vehreschild Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation Antimicrob Agents Chemother 54 2010 207 212
12. B. DePauw, T.J. Walsh, J.P. Donnelly, D.A. Stevens, J.E. Edwards, and T. Calandra Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 2008 1813 1821
13. K. Leventakos, R.E. Lewis, I.I. Raad, and D.P. Kontoyiannis Posaconazole plasma concentrations in hematological malignancy patients without mucositis or gut GVHD 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2009; San Francisco, CA 2009 ASM Press Washington, DC [abstract M-1054]
14. C. Eiden, J.C. Meniane, H. Peyriere, S. Eymard-Duvernay, P. Ceballos, and N. Fegueux Influence of food intake on posaconazole plasma concentrations: evidence of posaconazole therapeutic drug monitoring 49th Interscience Conference on Antimicrobial Agents and Chemotherapy 12-15 September 2009; San Francisco, CA 2009 ASM Press Washington, DC [abstract A1-425]
15. A.H. Saad, D.D. DePestel, and P.L. Carver Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants Pharmacotherapy 26 2006 1730 1744 (Pubitemid 44885328)